Companies: 10,795·Total market cap: $144.5T
Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZIANASDAQHealthcare● Active
$11.40
+$0.41(+3.73%)
Market Cap$18465617
P/E Ratio—
52W High$17.4
52W Low$4.86
SEC Filings
Foreign Private Issuer · Files 20-F / 6-K

Kazia Therapeutics Limited (KZIA) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001075880 · KZIA · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
3
Latest Form
2026-06-03
Most Recent
1999
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001075880 · Updated hourly · Not investment advice

Latest Annual Report

20-F · Annual Report (Foreign Issuer)FY
Filed Date
2025-11-07
Fiscal Year End
Nov 7, 2025
Accession No.
0001193125-25-272284
Primary Document
d908386d20f.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001075880 · Accession 0001193125-25-272284

Latest Key Filings

6-KQuarterly Report
REPORT OF FOREIGN PRIVATE ISSUER
2026-06-02
View 6-K on SEC
8-KCurrent Report

No recent filings

Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
3Initial Statement of Beneficial Ownership
3
2026-06-03
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-06-02
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-06-02
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-06-02
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-06-02
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-06-02
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-27
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-05-26
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-05-26
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-05-26
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-05-26
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-05-26
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-05-19
View
6-KCurrent Report (Foreign Issuer)
REPORT OF FOREIGN PRIVATE ISSUER
2026-04-27
View
424B3424B3
PROSPECTUS SUPPLEMENT
2026-04-15
View
Showing 1–15 of 942 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001075880  |  Exchange: NASDAQ · Healthcare

Kazia Therapeutics Limited (NASDAQ: KZIA) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1999. As a Healthcare sector company with CIK 0001075880, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Kazia Therapeutics Limited's most comprehensive regulatory disclosure. The most recent Kazia Therapeutics Limited 10-K was filed on 2025-11-07 for fiscal year ending 2025. Historical KZIA 10-K annual reports are available from 2006 through 2025.

Investors researching Kazia Therapeutics Limited SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
SILO SEC Filings →SNGX SEC Filings →CMND SEC Filings →TTNP SEC Filings →CNSP SEC Filings →INM SEC Filings →OGEN SEC Filings →CANF SEC Filings →
→ KZIA Financials→ KZIA Earnings→ KZIA Insider Trades

Frequently Asked Questions

KZIA SEC Filings · 8 questions

Kazia Therapeutics Limited (KZIA) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. Kazia Therapeutics Limited's CIK is 0001075880.

KZIA SEC filingsKazia Therapeutics Limited SEC documentsfind KZIA 10-K